Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2009 Results

CHARLOTTE, N.C., March 3, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release fourth quarter and full year results for the period ended...
February 26, 2010 08:58 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Raise $18.2 Million in Registered Direct Offering

CHARLOTTE, N.C., Feb. 26, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced it has obtained commitments from institutional investors to purchase approximately...
February 11, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Supports Initiation of Phase II Study of Droxidopa in Combination With Carbidopa in Adult Attention Deficit Hyperactivity Disorder

CHARLOTTE, N.C., Feb. 11, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic...
February 09, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces Advancements in Neurogenic Orthostatic Hypotension Registration Program

FDA Confirms Special Protocol Assessment for Study 301 Protocol for Study 306 Finalized, Study to Begin in the Second Quarter Northera Selected as US Brand Name for Droxidopa in...
February 03, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present at 12th Annual BIO CEO & Investor Conference

CHARLOTTE, N.C., Feb. 3, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 12th Annual BIO CEO & Investor Conference at 1:30 PM ET on...
December 15, 2009 08:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Granted Approval to Change the Primary Endpoint and Increase Enrollment in Droxidopa Pivotal Study 301

Top-line Data Expected in Third Quarter 2010 Chelsea Management to Host Conference Call Today at 10:00 AM EST CHARLOTTE, N.C., Dec. 15, 2009 (GLOBE NEWSWIRE) -- Chelsea...
December 14, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Subgroup Analysis of 44 Parkinson's Patients in Study 302 Shows Highly Statistically Significant Benefits of Droxidopa Therapy

CHARLOTTE, N.C., Dec. 14, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that new data from a subgroup analysis of the 44 Parkinson's Disease (PD) patients...
November 12, 2009 07:35 ET | Source: Chelsea Therapeutics

Results From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Presented at 20th Annual International Symposium on the Autonomic Nervous System

CHARLOTTE, N.C., Nov. 12, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that Horacio Kaufmann, M.D. will present results from Droxidopa Study 302 at the...
November 02, 2009 16:15 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Third Quarter 2009 Results

CHARLOTTE, N.C., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported financial results for the third quarter 2009. Chelsea's management team will host a...
November 02, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Appoints Dr. William D. Schwieterman Chief Medical Officer

CHARLOTTE, N.C, Nov. 2, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced the appointment of William D. Schwieterman, M.D., to the newly created position of...